Stocks · News reference

Regeneron Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.

Jul 30, 2026, 12:13 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

REGN

Source: benzinga
Observed: Jul 30, 2026, 12:13 PM
Checked: Jul 30, 2026, 12:13 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

The Motley FoolAug 21, 2026, 11:02 AMAndy Gould
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?
The article compares two biotech ETFs from Invesco: IBBQ, which offers broad diversification across 251 companies with a low 0.19% expense ratio, and PBE, which takes a concentrated approach with 31 holdings and a higher 1.73% dividend yield. IBBQ is recommended for long-term investors seeking low-cost exposure, while PBE appeals to income-focused investors willing to pay higher fees for selective, momentum-driven picks.
Read original at the-motley-fool
AMGN VRTX REGN
BenzingaAug 20, 2026, 1:25 PMVandana Singh
Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug
Regeneron Pharmaceuticals secured FDA approval for Pasatru, a novel monthly infusion therapy proven to reduce lesions in FOP patients.
Read original at benzinga
REGN
BenzingaAug 20, 2026, 10:33 AMRadhika Anilkumar Nadig
Bill Ackman Donates $400 Million in Pershing Square Stock to Build a Research Institute After His Daughter’s Severe Brain Hemorrhage
Bill Ackman gifted $400 million of his Pershing Square stake to a brain research foundation after his daughter's near-fatal hemorrhage.
Read original at benzinga
PS REGN
BenzingaAug 19, 2026, 6:02 PMBenzinga Newsdesk
Regeneron Pharmaceuticals Granted FDA Approval For Pasatru To Lower Formation Of New Heterotopic Ossification Lesions And Clinician-Assessed Flare-Ups In Adults With Fibrodysplasia Ossificans Progressiva
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO)
Read original at benzinga
REGN

Regeneron Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.

Connected markets

Related headlines

IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?

Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug

Bill Ackman Donates $400 Million in Pershing Square Stock to Build a Research Institute After His Daughter’s Severe Brain Hemorrhage

Regeneron Pharmaceuticals Granted FDA Approval For Pasatru To Lower Formation Of New Heterotopic Ossification Lesions And Clinician-Assessed Flare-Ups In Adults With Fibrodysplasia Ossificans Progressiva